The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction

Journal of Medical Biochemistry

Živković Irena¹  Minić Rajna¹  Stanojević-Pirković Marijana²  Anđelković Marija²  Lučić-Tomić Aleksandra³  Mijatović-Teodorović Ljiljana⁴  Živančević-Simonović Snežana⁵  Mihaljević Olgica⁵  Jovanović Zorica⁵ 

[1] Institute of Virology, Vaccines and Sera, Torlak, Department of Scientific Research, Belgrade, Serbia;University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, Kragujevac, Serbia;University of Kragujevac, Faculty of Medical Sciences, Department of Internal Medicine, Kragujevac, Serbia;University of Kragujevac, Faculty of Medical Sciences, Department of Nuclear Medicine, Kragujevac, Serbia;University of Kragujevac, Faculty of Medical Sciences, Department of Pathophysiology, Kragujevac, Serbia;

关键词: beta-cross-laps;    bone metabolism;    osteocalcin;    sclerostin;    thyroid dysfunction;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p<0.001), but positively with FT4 (r=0.696, p < 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps.

【 授权许可】

Unknown